Merck Agrees to Return Kuvan® Rights to BioMarin Pharmaceutical to Strengthen Focus on Core Business
Darmstadt, Germany (ots/PRNewswire) - - Agreement with BioMarin, a leading company in the treatment of genetic and rare diseases, also includes returning option to develop and commercialize Peg-Pal - Merck to receive upfront payment of EUR 340 million, plus up to EUR 185 million in additional milestones Merck, a ...